POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025. "This is a straightforward but important step in strengthening how we engage with U.S. i ...

Core Viewpoint - IGC Pharma, Inc. is set to host a conference call and webcast to discuss its operational progress for the second quarter and mid-year period ending September 30, 2025 [1] Company Summary - IGC Pharma is a clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease using AI technology [1] - The conference call is scheduled for November 17, 2025, at 11:00 a.m. Eastern Time [1]